<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33172304</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-7798</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Critical reviews in biochemistry and molecular biology</Title><ISOAbbreviation>Crit Rev Biochem Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Repeat RNA expansion disorders of the nervous system: post-transcriptional mechanisms and therapeutic strategies.</ArticleTitle><Pagination><StartPage>31</StartPage><EndPage>53</EndPage><MedlinePgn>31-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/10409238.2020.1841726</ELocationID><Abstract><AbstractText>Dozens of incurable neurological disorders result from expansion of short repeat sequences in both coding and non-coding regions of the transcriptome. Short repeat expansions underlie microsatellite repeat expansion (MRE) disorders including myotonic dystrophy (DM1, CUG<sub>50-3,500</sub> in <i>DMPK</i>; DM2, CCTG<sub>75-11,000</sub> in ZNF9), fragile X tremor ataxia syndrome (FXTAS, CGG<sub>50-200</sub> in FMR1), spinal bulbar muscular atrophy (SBMA, CAG<sub>40-55</sub> in AR), Huntington's disease (HD, CAG<sub>36-121</sub> in HTT), C9ORF72- amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD and C9-ALS/FTD, GGGGCC in C9ORF72), and many others, like ataxias. Recent research has highlighted several mechanisms that may contribute to pathology in this heterogeneous class of neurological MRE disorders - bidirectional transcription, intranuclear RNA foci, and repeat associated non-AUG (RAN) translation - which are the subject of this review. Additionally, many MRE disorders share similar underlying molecular pathologies that have been recently targeted in experimental and preclinical contexts. We discuss the therapeutic potential of versatile therapeutic strategies that may selectively target disrupted RNA-based processes and may be readily adaptable for the treatment of multiple MRE disorders. Collectively, the strategies under consideration for treatment of multiple MRE disorders include reducing levels of toxic RNA, preventing RNA foci formation, and eliminating the downstream cellular toxicity associated with peptide repeats produced by RAN translation. While treatments are still lacking for the majority of MRE disorders, several promising therapeutic strategies have emerged and will be evaluated within this review.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Joshua L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-4263-2829</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Krysten Leigh</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeo</LastName><ForeName>Gene W</ForeName><Initials>GW</Initials><Identifier Source="ORCID">0000-0002-0799-6037</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY029166</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS103172</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG069098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Rev Biochem Mol Biol</MedlineTA><NlmUniqueID>8903774</NlmUniqueID><ISSNLinking>1040-9238</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C564105">Fragile X Tremor Ataxia Syndrome</SupplMeshName><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001259" MajorTopicYN="N">Ataxia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005600" MajorTopicYN="N">Fragile X Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="N">Muscular Atrophy, Spinal</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009223" MajorTopicYN="N">Myotonic Dystrophy</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012323" MajorTopicYN="N">RNA Processing, Post-Transcriptional</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014202" MajorTopicYN="N">Tremor</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ASO</Keyword><Keyword MajorTopicYN="N">MRE</Keyword><Keyword MajorTopicYN="N">RAN translation</Keyword><Keyword MajorTopicYN="N">RNA</Keyword><Keyword MajorTopicYN="N">RNA foci</Keyword><Keyword MajorTopicYN="N">protein</Keyword><Keyword MajorTopicYN="N">rCas</Keyword><Keyword MajorTopicYN="N">repeat expansion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33172304</ArticleId><ArticleId IdType="mid">NIHMS1664564</ArticleId><ArticleId IdType="pmc">PMC8192115</ArticleId><ArticleId IdType="doi">10.1080/10409238.2020.1841726</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, Verdine V, Cox DBT, Kellner MJ, Regev A, et al. 2017. RNA targeting with CRISPR-Cas13. Nature. 550(7675):280&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5706658</ArticleId><ArticleId IdType="pubmed">28976959</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelbello AJ, Rzuczek SG, McKee KK, Chen JL, Olafson H, Cameron MD, Moss WN, Wang ET, Disney MD. 2019. Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model. Proc Natl Acad Sci USA. 116(16):7799&#x2013;7804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6475439</ArticleId><ArticleId IdType="pubmed">30926669</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza J, Steward C, Rueckert F, Widdison M, Coffman R, Afjei A, Noctor SC, Hagerman R, Hagerman P, Mart&#xed;nez-Cerde&#xf1;o V. 2015. Dysregulated iron metabolism in the choroid plexus in fragile X-associated tremor/ataxia syndrome. Brain Res. 1598:88&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4340768</ArticleId><ArticleId IdType="pubmed">25498860</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold FJ, Merry DE. 2019. Molecular mechanisms and therapeutics for SBMA/Kennedy&#x2019;s disease. Neurotherapeutics. 16(4):928&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985201</ArticleId><ArticleId IdType="pubmed">31686397</ArticleId></ArticleIdList></Reference><Reference><Citation>Aumiller WM, Cakmak FP, Davis BW, Keating CD. 2016. RNA-based coacervates as a model for membraneless organelles: formation, properties, and interfacial liposome assembly. Langmuir. 32(39):10042&#x2013;10053.</Citation><ArticleIdList><ArticleId IdType="pubmed">27599198</ArticleId></ArticleIdList></Reference><Reference><Citation>Banez-Coronel M, Ranum LPW. 2019. Repeat-associated non-AUG (RAN) translation: insights from pathology. Lab Invest. 99(7):929&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7219275</ArticleId><ArticleId IdType="pubmed">30918326</ArticleId></ArticleIdList></Reference><Reference><Citation>Barman P, Reddy D, Bhaumik SR. 2019. Mechanisms of antisense transcription initiation with implications in gene expression, genomic integrity and disease pathogenesis. Noncoding RNA. 5:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6468509</ArticleId><ArticleId IdType="pubmed">30669611</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R, Charizanis K, Manchanda M, Mohan A, Li M, Finn DJ, Goodwin M, Zhang C, Sobczak K, Thornton CA, et al. 2014. Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease. Mol Cell. 56(2):311&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224598</ArticleId><ArticleId IdType="pubmed">25263597</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R, Nelles DA, Pirie E, Blue SM, Marina RJ, Wang H, Chaim IA, Thomas JD, Zhang N, Nguyen V, et al. 2017. Elimination of toxic microsatellite repeat expansion RNA by RNA-targeting Cas9. Cell. 170(5):899&#x2013;912 e810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873302</ArticleId><ArticleId IdType="pubmed">28803727</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R, Nelles DA, Roth DM, Krach F, Nutter CA, Tadokoro T, Thomas JD, Sznajder LJ, Blue SM, Gutierrez HL, et al.
2020. The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1. Nat Biomed Eng. https://www.nature.com/articles/s41551-020-00607-7#citeas</Citation><ArticleIdList><ArticleId IdType="pubmed">32929188</ArticleId></ArticleIdList></Reference><Reference><Citation>Bavassano C, Eigentler A, Stanika R, Obermair GJ, Boesch S, Dechant G, Nat R. 2017. Bicistronic CACNA1A gene expression in neurons derived from spinocerebellar ataxia type 6 patient-induced pluripotent stem cells. Stem Cells Dev. 26(22):1612&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684673</ArticleId><ArticleId IdType="pubmed">28946818</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Gitler AD. 2018. Ataxin-2 is Droppin&#x2019; some knowledge. Neuron. 98(4):673&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">29772196</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehringer A, Bowser R. 2018. RNA nucleocytoplasmic transport defects in neurodegenerative diseases. Adv Neurobiol. 20:85&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">29916017</ArticleId></ArticleIdList></Reference><Reference><Citation>Bott LC, Badders NM, Chen KL, Harmison GG, Bautista E, Shih CC, Katsuno M, Sobue G, Taylor JP, Dantuma NP, et al. 2016. A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy. Hum Mol Genet. 25(10):1979&#x2013;1989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062587</ArticleId><ArticleId IdType="pubmed">26962150</ArticleId></ArticleIdList></Reference><Reference><Citation>Botta A, Vallo L, Rinaldi F, Bonifazi E, Amati F, Biancolella M, Gambardella S, Mancinelli E, Angelini C, Meola G, et al. 2007. Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2. Gene Expr. 13(6):339&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6032453</ArticleId><ArticleId IdType="pubmed">17708420</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandes MS, Gray NE. 2020. NRF2 as a therapeutic target in neurodegenerative diseases. ASN Neuro. 12: 1759091419899782</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6977098</ArticleId><ArticleId IdType="pubmed">31964153</ArticleId></ArticleIdList></Reference><Reference><Citation>Brangwynne CP, Tompa P, Pappu RV. 2015. Polymer physics of intracellular phase transitions. Nature Phys. 11(11): 899&#x2013;904.</Citation></Reference><Reference><Citation>Brezgin S, Kostyusheva A, Kostyushev D, Chulanov V. 2019. Dead Cas systems: types, principles, and applications. Int J Mol Sci. 20:6041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929090</ArticleId><ArticleId IdType="pubmed">31801211</ArticleId></ArticleIdList></Reference><Reference><Citation>Budworth H, McMurray CT. 2013. Bidirectional transcription of trinucleotide repeats: roles for excision repair. DNA Repair (Amst)). 12(8):672&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720788</ArticleId><ArticleId IdType="pubmed">23669397</ArticleId></ArticleIdList></Reference><Reference><Citation>Burguete AS, Almeida S, Gao FB, Kalb R, Akins MR, Bonini NM. 2015. GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. Elife. 4:e08881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758954</ArticleId><ArticleId IdType="pubmed">26650351</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammas A, Millevoi S. 2017. RNA G-quadruplexes: emerging mechanisms in disease. Nucleic Acids Res. 45(4): 1584&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389700</ArticleId><ArticleId IdType="pubmed">28013268</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda C, Tong XP. 2018. Huntington&#x2019;s disease: from basic science to therapeutics. CNS Neurosci Ther. 24(4):247&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6489829</ArticleId><ArticleId IdType="pubmed">29582586</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, Vakulskas CA, Collingwood MA, Zhang L, Bode NM, et al. 2019. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 25(2):249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199589</ArticleId><ArticleId IdType="pubmed">30692695</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen A, Wang PY, Yang YC, Huang YH, Yeh JJ, Chou YH, Cheng JT, Hong YR, Li SS. 2006. SUMO regulates the cytoplasmonuclear transport of its target protein Daxx. J Cell Biochem. 98(4):895&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">16475184</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Varani G. 2013. Engineering RNA-binding proteins for biology. Febs J. 280(16):3734&#x2013;3754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4052831</ArticleId><ArticleId IdType="pubmed">23742071</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi X, Gatti P, Papoian T. 2017. Safety of antisense oligonucleotide and siRNA-based therapeutics. Drug Discov Today. 22(5):823&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">28159625</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho DH, Thienes CP, Mahoney SE, Analau E, Filippova GN, Tapscott SJ. 2005. Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell. 20(3):483&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">16285929</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JM, Holehouse AS, Pappu RV. 2020. Physical principles underlying the complex biology of intracellular phase transitions. Annu Rev Biophys. 49:107&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">32004090</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SY, Lopez-Gonzalez R, Krishnan G, Phillips HL, Li AN, Seeley WW, Yao WD, Almeida S, Gao FB. 2019. C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. Nat Neurosci. 22(6): 851&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800116</ArticleId><ArticleId IdType="pubmed">31086314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JD, Pattamatta A, Ranum LPW. 2018. Repeat-associated non-ATG (RAN) translation. J Biol Chem. 293(42): 16127&#x2013;16141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6200949</ArticleId><ArticleId IdType="pubmed">30213863</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JD, Ranum LP. 2014. Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders. Curr Opin Genet Dev. 26:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4237677</ArticleId><ArticleId IdType="pubmed">24852074</ArticleId></ArticleIdList></Reference><Reference><Citation>Colak D, Zaninovic N, Cohen MS, Rosenwaks Z, Yang WY, Gerhardt J, Disney MD, Jaffrey SR. 2014. Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science. 343(6174):1002&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4357282</ArticleId><ArticleId IdType="pubmed">24578575</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B, Kellner MJ, Joung J, Zhang F. 2017. RNA editing with CRISPR-Cas13. Science. 358(6366):1019&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5793859</ArticleId><ArticleId IdType="pubmed">29070703</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumming SA, Hamilton MJ, Robb Y, Gregory H, McWilliam C, Cooper A, Adam B, McGhie J, Hamilton G, Herzyk P, et al.; Scottish Myotonic Dystrophy Consortium. 2018. De novo repeat interruptions are associated with reduced somatic instability and mild or absent clinical features in myotonic dystrophy type 1. Eur J Hum Genet. 26(11):1635&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6189127</ArticleId><ArticleId IdType="pubmed">29967337</ArticleId></ArticleIdList></Reference><Reference><Citation>Daughters RS, Tuttle DL, Gao W, Ikeda Y, Moseley ML, Ebner TJ, Swanson MS, Ranum LP. 2009. RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet. 5(8):e1000600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719092</ArticleId><ArticleId IdType="pubmed">19680539</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey AS, La Spada AR. 2018. Therapy development in Huntington disease: from current strategies to emerging opportunities. Am J Med Genet A. 176(4):842&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5975251</ArticleId><ArticleId IdType="pubmed">29218782</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Heusler AR, Mistry NA, Vidensky S, Daley EL, Poth EM, Hoover B, Fines DM, et al. 2013. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 80(2): 415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova PA, Bezprozvanny IB. 2019. Molecular mechanisms and therapeutics for spinocerebellar ataxia type 2. Neurotherapeutics. 16(4):1050&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985344</ArticleId><ArticleId IdType="pubmed">31435879</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers MM, Tran HD, Zalachoras I, Pepers BA, Meijer OC, den Dunnen JT, van Ommen GJ, Aartsma-Rus A, van Roon-Mom WM. 2013. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Neurobiol Dis. 58:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">23659897</ArticleId></ArticleIdList></Reference><Reference><Citation>Fardaei M, Rogers MT, Thorpe HM, Larkin K, Hamshere MG, Harper PS, Brook JD. 2002. Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet. 11(7):805&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">11929853</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z, Chen X, Wu X, Zhang M. 2019. Formation of biological condensates via phase separation: Characteristics, analytical methods, and physiological implications. J Biol Chem. 294(40):14823&#x2013;14835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6779427</ArticleId><ArticleId IdType="pubmed">31444270</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipovska A, Rackham O. 2011. Designer RNA-binding proteins: new tools for manipulating the transcriptome. RNA Biol. 8(6):978&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">21941129</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipovska A, Razif MF, Nygard KK, Rackham O. 2011. A universal code for RNA recognition by PUF proteins. Nat Chem Biol. 7(7):425&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">21572425</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiszer A, Ellison-Klimontowicz ME, Krzyzosiak WJ. 2016. Silencing of genes responsible for polyQ diseases using chemically modified single-stranded siRNAs. Acta Biochim Pol. 63(4):759&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">27770571</ArticleId></ArticleIdList></Reference><Reference><Citation>Flotho A, Melchior F. 2013. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem. 82: 357&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">23746258</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Mizielinska S, Nicoll AJ, Zloh M, Fisher EM, Parkinson G, Isaacs AM. 2012. C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G-quadruplexes. Sci Rep. 2:1016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3527825</ArticleId><ArticleId IdType="pubmed">23264878</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC, et al. 2015. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 525(7567):129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Taylor JP. 2017. The role of dipeptide repeats in C9ORF72-related ALS-FTD. Front Mol Neurosci. 10:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5303742</ArticleId><ArticleId IdType="pubmed">28243191</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu HJ, Hardy J, Duff KE. 2018. Selective vulnerability in neurodegenerative diseases. Nat Neurosci. 21(10):1350&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360529</ArticleId><ArticleId IdType="pubmed">30250262</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabryelczyk B, Cai H, Shi X, Sun Y, Swinkels PJM, Salentinig S, Pervushin K, Miserez A. 2019. Hydrogen bond guidance and aromatic stacking drive liquid-liquid phase separation of intrinsically disordered histidine-rich peptides. Nat Commun. 10(1):5465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6884462</ArticleId><ArticleId IdType="pubmed">31784535</ArticleId></ArticleIdList></Reference><Reference><Citation>Garriga-Canut M, Agustin-Pavon C, Herrmann F, Sanchez A, Dierssen M, Fillat C, Isalan M. 2012. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA. 109(45): E3136&#x2013;3145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3494930</ArticleId><ArticleId IdType="pubmed">23054839</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Chillon-Marinas C, Goginashvili A, Atwal RS, Artates JW, Tabet R, Wheeler VC, Bang AG, Cleveland DW, Lagier-Tourenne C. 2017. Polyglutamine-expanded huntingtin exacerbates age-related disruption of nuclear integrity and nucleocytoplasmic transport. Neuron. 94(1): 48&#x2013;57 e44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479704</ArticleId><ArticleId IdType="pubmed">28384474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Petrucelli L. 2018. Disease mechanisms of C9ORF72 repeat expansions. Cold Spring Harb Perspect Med. 8(4):a024224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5880161</ArticleId><ArticleId IdType="pubmed">28130314</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, et al. 2014. Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 159(3):647&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253859</ArticleId><ArticleId IdType="pubmed">25307932</ArticleId></ArticleIdList></Reference><Reference><Citation>Gipson TA, Neueder A, Wexler NS, Bates GP, Housman D. 2013. Aberrantly spliced HTT, a new player in Huntington&#x2019;s disease pathogenesis. RNA Biol. 10(11): 1647&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3907474</ArticleId><ArticleId IdType="pubmed">24256709</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KM, Glineburg MR, Kearse MG, Flores BN, Linsalata AE, Fedak SJ, Goldstrohm AC, Barmada SJ, Todd PK. 2017. RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nat Commun. 8(1):2005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5722904</ArticleId><ArticleId IdType="pubmed">29222490</ArticleId></ArticleIdList></Reference><Reference><Citation>Grima JC, Daigle JG, Arbez N, Cunningham KC, Zhang K, Ochaba J, Geater C, Morozko E, Stocksdale J, Glatzer JC, et al. 2017. Mutant Huntingtin disrupts the nuclear pore complex. Neuron. 94(1):93&#x2013;107 e106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5595097</ArticleId><ArticleId IdType="pubmed">28384479</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Rothstein JD. 2016. The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat Rev Neurosci. 17(6): 383&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7376590</ArticleId><ArticleId IdType="pubmed">27150398</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman P. 2013. Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms. Acta Neuropathol. 126(1):1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904666</ArticleId><ArticleId IdType="pubmed">23793382</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB Jr., Moine H, Kooy RF, Tassone F, Gantois I, Sonenberg N, Mandel JL, et al. 2017. Fragile X syndrome. Nat Rev Dis Primers. 3: 17065.</Citation><ArticleIdList><ArticleId IdType="pubmed">28960184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale MA, Johnson NE, Berglund JA. 2019. Repeat-associated RNA structure and aberrant splicing. Biochim Biophys Acta Gene Regul Mech. 1862(11&#x2013;12):194405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7099610</ArticleId><ArticleId IdType="pubmed">31323433</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannan AJ. 2018. Tandem repeats mediating genetic plasticity in health and disease. Nat Rev Genet. 19(5):286&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">29398703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hautbergue GM, Castelli LM, Ferraiuolo L, Sanchez-Martinez A, Cooper-Knock J, Higginbottom A, Lin YH, Bauer CS, Dodd JE, Myszczynska MA, et al. 2017. SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits. Nat Commun. 8:16063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504286</ArticleId><ArticleId IdType="pubmed">28677678</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewitt G, Carroll B, Sarallah R, Correia-Melo C, Ogrodnik M, Nelson G, Otten EG, Manni D, Antrobus R, Morgan BA, et al. 2016. SQSTM1/p62 mediates crosstalk between autophagy and the UPS in DNA repair. Autophagy. 12(10): 1917&#x2013;1930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391493</ArticleId><ArticleId IdType="pubmed">27391408</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Rong Z, Gong X, Zhou Z, Sharma VK, Xing C, Watts JK, Corey DR, Mootha VV. 2018. Oligonucleotides targeting TCF4 triplet repeat expansion inhibit RNA foci and missplicing in Fuchs&#x2019; dystrophy. Hum Mol Genet. 27(6): 1015&#x2013;1026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886168</ArticleId><ArticleId IdType="pubmed">29325021</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu S, Xie Z, Onishi A, Yu X, Jiang L, Lin J, Rho HS, Woodard C, Wang H, Jeong JS, et al. 2009. Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell. 139(3):610&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774939</ArticleId><ArticleId IdType="pubmed">19879846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M, Taniguchi-Ikeda M, Kato T, Shinkai Y, Tanaka S, Hagiwara H, Sasaki N, Masaki T, Matsumura K, Sonoo M, et al. 2020. Unexpected mutations by CRISPR-Cas9 CTG repeat excision in myotonic dystrophy and use of CRISPR interference as an alternative approach. Mol Ther Methods Clin Dev. 18:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7321784</ArticleId><ArticleId IdType="pubmed">32637445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiguro T, Sato N, Ueyama M, Fujikake N, Sellier C, Kanegami A, Tokuda E, Zamiri B, Gall-Duncan T, Mirceta M, et al. 2017. Regulatory role of RNA chaperone TDP-43 for RNA misfolding and repeat-associated translation in SCA31. Neuron. 94(1):108&#x2013;124 e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5681996</ArticleId><ArticleId IdType="pubmed">28343865</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa K, Nagai Y. 2019. Molecular mechanisms and future therapeutics for spinocerebellar ataxia type 31 (SCA31). Neurotherapeutics. 16(4):1106&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985187</ArticleId><ArticleId IdType="pubmed">31755042</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwahashi CK, Yasui DH, An HJ, Greco CM, Tassone F, Nannen K, Babineau B, Lebrilla CB, Hagerman RJ, Hagerman PJ. 2006. Protein composition of the intranuclear inclusions of FXTAS. Brain. 129(Pt 1):256&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246864</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A, Vale RD. 2017. RNA phase transitions in repeat expansion disorders. Nature. 546(7657):243&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5555642</ArticleId><ArticleId IdType="pubmed">28562589</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. 2017. Huntington&#x2019;s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med. 7(7):a024240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5495055</ArticleId><ArticleId IdType="pubmed">27940602</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107; A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW, Sun S, Herdy JR, Bieri G, et al. 2015. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci. 18(9):1226&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Klug A. 2010. The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem. 79:213&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">20192761</ArticleId></ArticleIdList></Reference><Reference><Citation>Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhirev MN, Hsu PD. 2018. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell. 173(3):665&#x2013;676 e614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5910255</ArticleId><ArticleId IdType="pubmed">29551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Koole W, van Schendel R, Karambelas AE, van Heteren JT, Okihara KL, Tijsterman M. 2014. A polymerase thetadependent repair pathway suppresses extensive genomic instability at endogenous G4 DNA sites. Nat Commun. 5: 3216.</Citation><ArticleIdList><ArticleId IdType="pubmed">24496117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, et al. 2012. Sustained therapeutic reversal of Huntington&#x2019;s disease by transient repression of huntingtin synthesis. Neuron. 74(6):1031&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383626</ArticleId><ArticleId IdType="pubmed">22726834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotowska-Zimmer A, Ostrovska Y, Olejniczak M. 2020. Universal RNAi triggers for the specific inhibition of mutant Huntingtin, atrophin-1, ataxin-3, and ataxin-7 expression. Mol Ther Nucleic Acids. 19:562&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6957814</ArticleId><ArticleId IdType="pubmed">31927329</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer NJ, Haney MS, Morgens DW, Jovicic A, Couthouis J, Li A, Ousey J, Ma R, Bieri G, Tsui CK, et al. 2018. CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity. Nat Genet. 50(4):603&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893388</ArticleId><ArticleId IdType="pubmed">29507424</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari D, Usdin K. 2014. Polycomb group complexes are recruited to reactivated FMR1 alleles in Fragile X syndrome in response to FMR1 transcription. Hum Mol Genet. 23(24): 6575&#x2013;6583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240206</ArticleId><ArticleId IdType="pubmed">25055869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari D, Usdin K. 2016. Sustained expression of FMR1 mRNA from reactivated fragile X syndrome alleles after treatment with small molecules that prevent trimethylation of H3K27. Hum Mol Genet. 25(17):3689&#x2013;3698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5216614</ArticleId><ArticleId IdType="pubmed">27378697</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. 1991. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 352(6330): 77&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladd PD, Smith LE, Rabaia NA, Moore JM, Georges SA, Hansen RS, Hagerman RJ, Tassone F, Tapscott SJ, Filippova GN. 2007. An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet. 16(24):3174&#x2013;3187.</Citation><ArticleIdList><ArticleId IdType="pubmed">17921506</ArticleId></ArticleIdList></Reference><Reference><Citation>Leavitt BR, Tabrizi SJ. 2020. Antisense oligonucleotides for neurodegeneration. Science. 367(6485):1428&#x2013;1429.</Citation><ArticleIdList><ArticleId IdType="pubmed">32217715</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, Chen HJ, Peres JN, Gomez-Deza J, Attig J, Stalekar M, Troakes C, Nishimura AL, Scotter EL, Vance C, et al. 2013. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 5(5):1178&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang XH, Sun H, Nichols JG, Crooke ST. 2017. RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther. 25(9):2075&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5589097</ArticleId><ArticleId IdType="pubmed">28663102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP, Shakkottai VG, Albin RL. 2019. Polyglutamine repeats in neurodegenerative diseases. Annu Rev Pathol. 14:1&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6387631</ArticleId><ArticleId IdType="pubmed">30089230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Dent SY, Wilson JH, Wells RD, Napierala M. 2010. R loops stimulate genetic instability of CTG.CAG repeats. Proc Natl Acad Sci USA. 107(2):692&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818888</ArticleId><ArticleId IdType="pubmed">20080737</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J, Hnisz D, Li CH, Yuan B, Xu C, et al. 2018. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell. 172(5):979&#x2013;992 e976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375087</ArticleId><ArticleId IdType="pubmed">29456084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R, Lu Y, Gendron TF, Karydas A, Tran H, Yang D, Petrucelli L, Miller BL, Almeida S, Gao FB. 2016. Poly(GR) in C9ORF72-related ALS/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in iPSC-derived motor neurons. Neuron. 92(2):383&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Herren AW, Espinal G, Randol J, McLaughlin B, Martinez-Cerdeno V, Pessah IN, Hagerman RJ, Hagerman PJ. 2019. Composition of the intranuclear inclusions of fragile X-associated Tremor/Ataxia syndrome. Acta Neuropathol Commun. 7(1):143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6720097</ArticleId><ArticleId IdType="pubmed">31481131</ArticleId></ArticleIdList></Reference><Reference><Citation>Mankodi A, Urbinati CR, Yuan QP, Moxley RT, Sansone V, Krym M, Henderson D, Schalling M, Swanson MS, Thornton CA. 2001. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet. 10(19):2165&#x2013;2170.</Citation><ArticleIdList><ArticleId IdType="pubmed">11590133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Rollinson S, Robinson A, Bennion Callister J, Thompson JC, Snowden JS, Gendron T, Petrucelli L, Masuda-Suzukake M, Hasegawa M, et al. 2013. Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun. 1:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893586</ArticleId><ArticleId IdType="pubmed">24252525</ArticleId></ArticleIdList></Reference><Reference><Citation>Markmiller S, Soltanieh S, Server KL, Mak R, Jin W, Fang MY, Luo EC, Krach F, Yang D, Sen A, et al. 2018. Context-dependent and disease-specific diversity in protein interactions within stress granules. Cell. 172(3):590&#x2013;604 e513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5969999</ArticleId><ArticleId IdType="pubmed">29373831</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthaei M, Hribek A, Clahsen T, Bachmann B, Cursiefen C, Jun AS. 2019. Fuchs endothelial corneal dystrophy: clinical, genetic, pathophysiologic, and therapeutic aspects. Annu Rev Vis Sci. 5:151&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">31525145</ArticleId></ArticleIdList></Reference><Reference><Citation>Maziuk B, Ballance HI, Wolozin B. 2017. Dysregulation of RNA binding protein aggregation in neurodegenerative disorders. Front Mol Neurosci. 10:89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378767</ArticleId><ArticleId IdType="pubmed">28420962</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland KN, Liu J, Landrian I, Gao R, Sarkar PS, Raskin S, Moscovich M, Gatto EM, Teive HA, Ochoa A, et al. 2013. Paradoxical effects of repeat interruptions on spinocerebellar ataxia type 10 expansions and repeat instability. Eur J Hum Genet. 21(11):1272&#x2013;1276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3798839</ArticleId><ArticleId IdType="pubmed">23443018</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh CS, Aung-Htut MT, Fletcher S, Wilton SD. 2019. Removal of the polyglutamine repeat of Ataxin-3 by redirecting pre-mRNA processing. Int J Mol Sci. 20:5434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6862616</ArticleId><ArticleId IdType="pubmed">31683630</ArticleId></ArticleIdList></Reference><Reference><Citation>McLoughlin HS, Moore LR, Paulson HL. 2020. Pathogenesis of SCA3 and implications for other polyglutamine diseases. Neurobiol Dis. 134:104635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980715</ArticleId><ArticleId IdType="pubmed">31669734</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray CT. 2010. Mechanisms of trinucleotide repeat instability during human development. Nat Rev Genet. 11(11):786&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175376</ArticleId><ArticleId IdType="pubmed">20953213</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra C, Lin F, Kalsotra A. 2018. Deregulation of RNA metabolism in microsatellite expansion diseases. Adv Neurobiol. 20:213&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323645</ArticleId><ArticleId IdType="pubmed">29916021</ArticleId></ArticleIdList></Reference><Reference><Citation>Moseley ML, Zu T, Ikeda Y, Gao W, Mosemiller AK, Daughters RS, Chen G, Weatherspoon MR, Clark HB, Ebner TJ, et al. 2006. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat Genet. 38(7):758&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">16804541</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelles DA, Fang MY, O&#x2019;Connell MR, Xu JL, Markmiller SJ, Doudna JA, Yeo GW. 2016. Programmable RNA tracking in live cells with CRISPR/Cas9. Cell. 165(2):488&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826288</ArticleId><ArticleId IdType="pubmed">26997482</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson DL, Orr HT, Warren ST. 2013. The unstable repeats-three evolving faces of neurological disease. Neuron. 77(5):825&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3608403</ArticleId><ArticleId IdType="pubmed">23473314</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L, Cleary JD, Ranum LPW. 2019. Repeat-associated non-ATG translation: molecular mechanisms and contribution to neurological disease. Annu Rev Neurosci. 42: 227&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687071</ArticleId><ArticleId IdType="pubmed">30909783</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbacher JK, Tabet R, Yeo GW, Lagier-Tourenne C. 2019. Disruption of RNA metabolism in neurological diseases and emerging therapeutic interventions. Neuron. 102(2): 294&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545120</ArticleId><ArticleId IdType="pubmed">30998900</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira AM, Cardoso SM, Ribeiro M, Seixas RS, Silva AM, Rego AC. 2015. Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington&#x2019;s disease mouse striatal cells. Neurochem Int. 91:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">26476055</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi H, Kino Y, Morita T, Futai E, Sasagawa N, Ishiura S. 2008. MBNL1 associates with YB-1 in cytoplasmic stress granules. J Neurosci Res. 86(9):1994&#x2013;2002.</Citation><ArticleIdList><ArticleId IdType="pubmed">18335541</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr HT, Zoghbi HY. 2007. Trinucleotide repeat disorders. Annu Rev Neurosci. 30:575&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">17417937</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza F, Lozupone M, Seripa D, Daniele A, Watling M, Giannelli G, Imbimbo BP. 2020. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat Rev Neurol. 16(4):213&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">32203398</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul B, Montoya G. 2020. CRISPR-Cas12a: functional overview and applications. Biomed J. 43(1):8&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7090318</ArticleId><ArticleId IdType="pubmed">32200959</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S, Dansithong W, Jog SP, Holt I, Mittal S, Brook JD, Morris GE, Comai L, Reddy S. 2011. Expanded CUG repeats dysregulate RNA splicing by altering the stoichiometry of the muscleblind 1 complex. J. Biol. Chem. 286(44): 38427&#x2013;38438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207417</ArticleId><ArticleId IdType="pubmed">21900255</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson H. 2018. Repeat expansion diseases. Handb Clin Neurol. 147:105&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6485936</ArticleId><ArticleId IdType="pubmed">29325606</ArticleId></ArticleIdList></Reference><Reference><Citation>Perbellini R, Greco S, Sarra-Ferraris G, Cardani R, Capogrossi MC, Meola G, Martelli F. 2011. Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul Disord. 21(2):81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">21169019</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersson OJ, Aagaard L, Jensen TG, Damgaard CK. 2015. Molecular mechanisms in DM1 &#x2013; a focus on foci. Nucleic Acids Res. 43(4):2433&#x2013;2441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4344492</ArticleId><ArticleId IdType="pubmed">25605794</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto BS, Saxena T, Oliveira R, Mendez-Gomez HR, Cleary JD, Denes LT, McConnell O, Arboleda J, Xia G, Swanson MS, et al. 2017. Impeding transcription of expanded microsatellite repeats by deactivated Cas9. Mol Cell. 68(3):479&#x2013;490 e475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013302</ArticleId><ArticleId IdType="pubmed">29056323</ArticleId></ArticleIdList></Reference><Reference><Citation>Quenault T, Lithgow T, Traven A. 2011. PUF proteins: repression, activation and mRNA localization. Trends Cell Biol. 21(2):104&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">21115348</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K, Jenquin JR, McConnell OL, Cleary JD, Richardson JI, Pinto BS, Haerle MC, Delgado E, Planco L, Nakamori M, et al. 2019. A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels. Proc Natl Acad Sci USA. 116(42): 20991&#x2013;21000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800345</ArticleId><ArticleId IdType="pubmed">31570586</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi C, Wood MJA. 2018. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 14(1):9&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">29192260</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez CM, Wright SE, Kearse MG, Haenfler JM, Flores BN, Liu Y, Ifrim MF, Glineburg MR, Krans A, Jafar-Nejad P, et al. 2020. A native function for RAN translation and CGG repeats in regulating fragile X protein synthesis. Nat Neurosci. 23(3):386&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668390</ArticleId><ArticleId IdType="pubmed">32066985</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohilla KJ, Gagnon KT. 2017. RNA biology of disease-associated microsatellite repeat expansions. Acta Neuropathol Commun. 5(1):63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5574247</ArticleId><ArticleId IdType="pubmed">28851463</ArticleId></ArticleIdList></Reference><Reference><Citation>Roselli F, Caroni P. 2015. From intrinsic firing properties to selective neuronal vulnerability in neurodegenerative diseases. Neuron. 85(5):901&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">25741719</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnicki DD, Holmes SE, Lin MW, Thornton CA, Ross CA, Margolis RL. 2007. Huntington&#x2019;s disease-like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol. 61(3): 272&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">17387722</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, Smith DL, Faull RL, Roos RA, Howland D, et al. 2013. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci USA. 110(6):2366&#x2013;2370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568346</ArticleId><ArticleId IdType="pubmed">23341618</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt MHM, Pearson CE. 2016. Disease-associated repeat instability and mismatch repair. DNA Repair (Amst)). 38: 117&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">26774442</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C, Freyermuth F, Tabet R, Tran T, He F, Ruffenach F, Alunni V, Moine H, Thibault C, Page A, et al. 2013. Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep. 3(3):869&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639429</ArticleId><ArticleId IdType="pubmed">23478018</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C, Rau F, Liu Y, Tassone F, Hukema RK, Gattoni R, Schneider A, Richard S, Willemsen R, Elliott DJ, et al. 2010. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. Embo J. 29(7):1248&#x2013;1261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857464</ArticleId><ArticleId IdType="pubmed">20186122</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj BT, Livesey MR, Zhao C, Gregory JM, James OT, Cleary EM, Chouhan AK, Gane AB, Perkins EM, Dando O, et al. 2018. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2-permeable AMPA receptor-mediated excitotoxicity. Nat Commun. 9(1):347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi KY, Mori E, Nizami ZF, Lin Y, Kato M, Xiang S, Wu LC, Ding M, Yu Y, Gall JG, et al. 2017. Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proc Natl Acad Sci USA. 114(7): E1111&#x2013;E1117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5320981</ArticleId><ArticleId IdType="pubmed">28069952</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada MK, Sanbonmatsu R, Yamaguchi-Kabata Y, Yamasaki C, Suzuki Y, Chakraborty R, Gojobori T, Imanishi T. 2016. Selection pressure on human STR loci and its relevance in repeat expansion disease. Mol Genet Genomics. 291(5): 1851&#x2013;1869.</Citation><ArticleIdList><ArticleId IdType="pubmed">27290643</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J, Charizanis K, Swanson MS. 2009. Pathogenic RNAs in microsatellite expansion disease. Neurosci Lett. 466(2): 99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2767409</ArticleId><ArticleId IdType="pubmed">19647781</ArticleId></ArticleIdList></Reference><Reference><Citation>Siboni RB, Nakamori M, Wagner SD, Struck AJ, Coonrod LA, Harriott SA, Cass DM, Tanner MK, Berglund JA. 2015. Actinomycin D specifically reduces expanded CUG repeat RNA in myotonic dystrophy models. Cell Rep. 13(11): 2386&#x2013;2394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4691565</ArticleId><ArticleId IdType="pubmed">26686629</ArticleId></ArticleIdList></Reference><Reference><Citation>Simhadri VL, McGill J, McMahon S, Wang J, Jiang H, Sauna ZE. 2018. Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population. Mol Ther Methods Clin Dev. 10:105&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6070699</ArticleId><ArticleId IdType="pubmed">30073181</ArticleId></ArticleIdList></Reference><Reference><Citation>Smargon AA, Shi YJ, Yeo GW. 2020. RNA-targeting CRISPR systems from metagenomic discovery to transcriptomic engineering. Nat Cell Biol. 22(2):143&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008746</ArticleId><ArticleId IdType="pubmed">32015437</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulej AA, Tuszynska I, Skowronek KJ, Nowotny M, Bujnicki JM. 2012. Sequence-specific cleavage of the RNA strand in DNA-RNA hybrids by the fusion of ribonuclease H with a zinc finger. Nucleic Acids Res. 40(22):11563&#x2013;11570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3526281</ArticleId><ArticleId IdType="pubmed">23042681</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W, Van Den Bosch L. 2020. RNA toxicity in non-coding repeat expansion disorders. Embo J. 39(1):e101112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939197</ArticleId><ArticleId IdType="pubmed">31721251</ArticleId></ArticleIdList></Reference><Reference><Citation>Tassone F, Iwahashi C, Hagerman PJ. 2004. FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol. 1(2):103&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17179750</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton CA. 2014. Myotonic dystrophy. Neurol Clin. 32(3): 705&#x2013;719, viii.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105852</ArticleId><ArticleId IdType="pubmed">25037086</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd PK, Paulson HL. 2010. RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol. 67(3): 291&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852186</ArticleId><ArticleId IdType="pubmed">20373340</ArticleId></ArticleIdList></Reference><Reference><Citation>Toonen LJA, Rigo F, van Attikum H, van Roon-Mom WMC. 2017. Antisense oligonucleotide-mediated removal of the polyglutamine repeat in spinocerebellar Ataxia type 3 mice. Mol Ther Nucleic Acids. 8:232&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504086</ArticleId><ArticleId IdType="pubmed">28918024</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbanek MO, Fiszer A, Krzyzosiak WJ. 2017. Reduction of Huntington&#x2019;s disease RNA foci by CAG repeat-targeting reagents. Front Cell Neurosci. 11:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5368221</ArticleId><ArticleId IdType="pubmed">28400719</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbanek MO, Krzyzosiak WJ. 2016. RNA FISH for detecting expanded repeats in human diseases. Methods. 98: 115&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">26615955</ArticleId></ArticleIdList></Reference><Reference><Citation>van Cruchten RTP, Wieringa B, Wansink DG. 2019. Expanded CUG repeats in DMPK transcripts adopt diverse hairpin conformations without influencing the structure of the flanking sequences. RNA. 25(4):481&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426290</ArticleId><ArticleId IdType="pubmed">30700578</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LL, Wansleeben C, Zhao SL, Miao P, Paschen W, Yang W. 2014. SUMO2 is essential while SUMO3 is dispensable for mouse embryonic development. EMBO Rep. 15(8): 878&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197045</ArticleId><ArticleId IdType="pubmed">24891386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME, Taubes A, Chen R, Miller BL, Sephton CF, Gelfand JM, Minami S, Boscardin J, Martens LH, Seeley WW, et al. 2014. Early retinal neurodegeneration and impaired Ranmediated nuclear import of TDP-43 in progranulin-deficient FTLD. J Exp Med. 211(10):1937&#x2013;1945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172214</ArticleId><ArticleId IdType="pubmed">25155018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel HJ, Hunsaker MR, Greco CM, Willemsen R, Berman RF. 2010. Ubiquitin-positive intranuclear inclusions in neuronal and glial cells in a mouse model of the fragile X pre-mutation. Brain Res. 1318:155&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086812</ArticleId><ArticleId IdType="pubmed">20051238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, Wentworth BM, Bennett CF, Thornton CA. 2012. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature. 488(7409):111&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4221572</ArticleId><ArticleId IdType="pubmed">22859208</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT, Thornton CA. 2009. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science. 325(5938):336&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4109973</ArticleId><ArticleId IdType="pubmed">19608921</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Hulshoff MS, Tan X, Zeisberg M, Zeisberg EM. 2020. CRISPR/Cas derivatives as novel gene modulating tools: possibilities and in vivo applications. Int J Mol Sci. 21: 3038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7246536</ArticleId><ArticleId IdType="pubmed">32344896</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada SB, Gendron TF, Niccoli T, Genuth NR, Grosely R, Shi Y, Glaria I, Kramer NJ, Nakayama L, Fang S, et al. 2019. RPS25 is required for efficient RAN translation of C9orf72 and other neurodegenerative disease-associated nucleotide repeats. Nat Neurosci. 22(9):1383&#x2013;1388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6713615</ArticleId><ArticleId IdType="pubmed">31358992</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P, Wang Y, Hoang D, Tinkham M, Patel A, Sun MA, Wolf G, Baker M, Chien HC, Lai KN, et al. 2017. A placental growth factor is silenced in mouse embryos by the zinc finger protein ZFP568. Science. 356(6339):757&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309218</ArticleId><ArticleId IdType="pubmed">28522536</ArticleId></ArticleIdList></Reference><Reference><Citation>Yrigollen CM, Durbin-Johnson B, Gane L, Nelson DL, Hagerman R, Hagerman PJ, Tassone F. 2012. AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genet Med. 14(8): 729&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990283</ArticleId><ArticleId IdType="pubmed">22498846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Elbaum-Garfinkle S, Langdon EM, Taylor N, Occhipinti P, Bridges AA, Brangwynne CP, Gladfelter AS. 2015a. RNA controls PolyQ protein phase transitions. Mol Cell. 60(2):220&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5221516</ArticleId><ArticleId IdType="pubmed">26474065</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, et al. 2015b. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 525(7567):56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Ashizawa T. 2017. RNA toxicity and foci formation in microsatellite expansion diseases. Curr Opin Genet Dev. 44:17&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5447490</ArticleId><ArticleId IdType="pubmed">28208060</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen-West K, Xu YF, Katzman RB, Gass J, Murray ME, Shinohara M, et al. 2016. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci. 19(5):668&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, Margolis J, Peterson M, Markowski TW, Ingram MA, et al. 2011. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci USA. 108(1): 260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>